# Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis

> **NCT02178306** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 82 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan low dose
- **DRUG:** Telmisartan high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02178306
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09
- **Primary completion:** 2002-04
- **Final completion:** —
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2014-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02178306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02178306, "Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02178306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*